GLOBUS MEDICAL INC - A (GMED) Stock Fundamental Analysis
NYSE:GMED • US3795772082
88.53 USD
+1.31 (+1.5%)
Last: Feb 13, 2026, 09:48 AM
Taking everything into account, GMED scores 6 out of 10 in our fundamental rating. GMED was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making GMED a very profitable company, without any liquidiy or solvency issues. GMED is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, GMED could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year GMED was profitable.
- GMED had a positive operating cash flow in the past year.
- GMED had positive earnings in each of the past 5 years.
- Each year in the past 5 years GMED had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of GMED (8.32%) is better than 90.32% of its industry peers.
- GMED's Return On Equity of 9.63% is amongst the best of the industry. GMED outperforms 85.48% of its industry peers.
- GMED's Return On Invested Capital of 8.29% is amongst the best of the industry. GMED outperforms 84.95% of its industry peers.
- GMED had an Average Return On Invested Capital over the past 3 years of 5.79%. This is below the industry average of 8.83%.
- The last Return On Invested Capital (8.29%) for GMED is above the 3 year average (5.79%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.32% | ||
| ROE | 9.63% | ||
| ROIC | 8.29% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)5.79%
ROIC(5y)6.37%
1.3 Margins
- GMED has a better Profit Margin (15.30%) than 91.94% of its industry peers.
- GMED's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 17.37%, GMED belongs to the best of the industry, outperforming 88.71% of the companies in the same industry.
- In the last couple of years the Operating Margin of GMED has declined.
- GMED's Gross Margin of 67.05% is fine compared to the rest of the industry. GMED outperforms 72.04% of its industry peers.
- In the last couple of years the Gross Margin of GMED has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.37% | ||
| PM (TTM) | 15.3% | ||
| GM | 67.05% |
OM growth 3Y-23.93%
OM growth 5Y-16.84%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-7.75%
GM growth 5Y-5.24%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GMED is destroying value.
- Compared to 1 year ago, GMED has more shares outstanding
- Compared to 5 years ago, GMED has more shares outstanding
- The debt/assets ratio for GMED is higher compared to a year ago.
2.2 Solvency
- GMED has an Altman-Z score of 11.61. This indicates that GMED is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 11.61, GMED belongs to the best of the industry, outperforming 91.40% of the companies in the same industry.
- GMED has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
- GMED has a Debt to FCF ratio of 0.00. This is amongst the best in the industry. GMED outperforms 94.09% of its industry peers.
- GMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- GMED has a better Debt to Equity ratio (0.00) than 76.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.61 |
ROIC/WACC0.85
WACC9.79%
2.3 Liquidity
- A Current Ratio of 4.13 indicates that GMED has no problem at all paying its short term obligations.
- GMED's Current ratio of 4.13 is fine compared to the rest of the industry. GMED outperforms 69.89% of its industry peers.
- A Quick Ratio of 2.47 indicates that GMED has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.47, GMED is in the better half of the industry, outperforming 60.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.13 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 22.76% over the past year.
- The Earnings Per Share has been growing by 13.19% on average over the past years. This is quite good.
- GMED shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.75%.
- Measured over the past years, GMED shows a very strong growth in Revenue. The Revenue has been growing by 26.25% on average per year.
EPS 1Y (TTM)22.76%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%42.17%
Revenue 1Y (TTM)11.75%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%22.91%
3.2 Future
- GMED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.62% yearly.
- GMED is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.32% yearly.
EPS Next Y25.18%
EPS Next 2Y17.67%
EPS Next 3Y15.95%
EPS Next 5Y10.62%
Revenue Next Year16.37%
Revenue Next 2Y12.42%
Revenue Next 3Y10.29%
Revenue Next 5Y8.32%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 24.87 indicates a rather expensive valuation of GMED.
- 76.34% of the companies in the same industry are more expensive than GMED, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 27.67, GMED is valued at the same level.
- With a Price/Forward Earnings ratio of 20.36, GMED is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 80.11% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.69, GMED is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 20.36 |
4.2 Price Multiples
- 82.26% of the companies in the same industry are more expensive than GMED, based on the Enterprise Value to EBITDA ratio.
- 88.71% of the companies in the same industry are more expensive than GMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.79 | ||
| EV/EBITDA | 14.88 |
4.3 Compensation for Growth
- GMED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- GMED has a very decent profitability rating, which may justify a higher PE ratio.
- GMED's earnings are expected to grow with 15.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.99
PEG (5Y)1.89
EPS Next 2Y17.67%
EPS Next 3Y15.95%
5. Dividend
5.1 Amount
- GMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:GMED (2/13/2026, 9:48:33 AM)
88.53
+1.31 (+1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-19 2026-02-19/amc
Inst Owners108.37%
Inst Owner Change-2.65%
Ins Owners0.71%
Ins Owner Change1.12%
Market Cap11.85B
Revenue(TTM)2.77B
Net Income(TTM)423.78M
Analysts77.14
Price Target107.03 (20.9%)
Short Float %3.51%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.7%
Min EPS beat(2)11.6%
Max EPS beat(2)47.79%
EPS beat(4)3
Avg EPS beat(4)14.87%
Min EPS beat(4)-10.39%
Max EPS beat(4)47.79%
EPS beat(8)6
Avg EPS beat(8)14.29%
EPS beat(12)9
Avg EPS beat(12)10.13%
EPS beat(16)11
Avg EPS beat(16)6.78%
Revenue beat(2)1
Avg Revenue beat(2)0.59%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)-1.24%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)2.67%
Revenue beat(8)5
Avg Revenue beat(8)-0.3%
Revenue beat(12)7
Avg Revenue beat(12)-0.72%
Revenue beat(16)8
Avg Revenue beat(16)-0.84%
PT rev (1m)8.92%
PT rev (3m)30.67%
EPS NQ rev (1m)5.56%
EPS NQ rev (3m)16.33%
EPS NY rev (1m)1.55%
EPS NY rev (3m)20.23%
Revenue NQ rev (1m)2.8%
Revenue NQ rev (3m)2.88%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)2.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 20.36 | ||
| P/S | 4.28 | ||
| P/FCF | 20.79 | ||
| P/OCF | 16.57 | ||
| P/B | 2.69 | ||
| P/tB | 5.41 | ||
| EV/EBITDA | 14.88 |
EPS(TTM)3.56
EY4.02%
EPS(NY)4.35
Fwd EY4.91%
FCF(TTM)4.26
FCFY4.81%
OCF(TTM)5.34
OCFY6.04%
SpS20.69
BVpS32.87
TBVpS16.37
PEG (NY)0.99
PEG (5Y)1.89
Graham Number51.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.32% | ||
| ROE | 9.63% | ||
| ROCE | 10.39% | ||
| ROIC | 8.29% | ||
| ROICexc | 9.06% | ||
| ROICexgc | 18.9% | ||
| OM | 17.37% | ||
| PM (TTM) | 15.3% | ||
| GM | 67.05% | ||
| FCFM | 20.58% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)5.79%
ROIC(5y)6.37%
ROICexc(3y)7.27%
ROICexc(5y)8.25%
ROICexgc(3y)12.85%
ROICexgc(5y)12.55%
ROCE(3y)7.25%
ROCE(5y)7.98%
ROICexgc growth 3Y0.63%
ROICexgc growth 5Y-2.08%
ROICexc growth 3Y-23.17%
ROICexc growth 5Y-16.59%
OM growth 3Y-23.93%
OM growth 5Y-16.84%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-7.75%
GM growth 5Y-5.24%
F-Score9
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 52.62% | ||
| Cap/Sales | 5.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 94.46% | ||
| Profit Quality | 134.49% | ||
| Current Ratio | 4.13 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | 11.61 |
F-Score9
WACC9.79%
ROIC/WACC0.85
Cap/Depr(3y)69.29%
Cap/Depr(5y)78.11%
Cap/Sales(3y)5.6%
Cap/Sales(5y)6.16%
Profit Quality(3y)194.29%
Profit Quality(5y)172.4%
High Growth Momentum
Growth
EPS 1Y (TTM)22.76%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%42.17%
EPS Next Y25.18%
EPS Next 2Y17.67%
EPS Next 3Y15.95%
EPS Next 5Y10.62%
Revenue 1Y (TTM)11.75%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%22.91%
Revenue Next Year16.37%
Revenue Next 2Y12.42%
Revenue Next 3Y10.29%
Revenue Next 5Y8.32%
EBIT growth 1Y109.04%
EBIT growth 3Y5%
EBIT growth 5Y5%
EBIT Next Year72.33%
EBIT Next 3Y26.97%
EBIT Next 5Y17.51%
FCF growth 1Y341.47%
FCF growth 3Y22.69%
FCF growth 5Y31.98%
OCF growth 1Y252.66%
OCF growth 3Y23.51%
OCF growth 5Y24.8%
GLOBUS MEDICAL INC - A / GMED FAQ
What is the ChartMill fundamental rating of GLOBUS MEDICAL INC - A (GMED) stock?
ChartMill assigns a fundamental rating of 6 / 10 to GMED.
Can you provide the valuation status for GLOBUS MEDICAL INC - A?
ChartMill assigns a valuation rating of 6 / 10 to GLOBUS MEDICAL INC - A (GMED). This can be considered as Fairly Valued.
Can you provide the profitability details for GLOBUS MEDICAL INC - A?
GLOBUS MEDICAL INC - A (GMED) has a profitability rating of 7 / 10.
What are the PE and PB ratios of GLOBUS MEDICAL INC - A (GMED) stock?
The Price/Earnings (PE) ratio for GLOBUS MEDICAL INC - A (GMED) is 24.87 and the Price/Book (PB) ratio is 2.69.
Can you provide the expected EPS growth for GMED stock?
The Earnings per Share (EPS) of GLOBUS MEDICAL INC - A (GMED) is expected to grow by 25.18% in the next year.